In an experimental allergic conjunctivitis model using wild and AnxA1-null Balb/c mice, administration of the AnxA1-N-terminal region mimetic peptide (Ac2-26) was effective in reducing interleukin (IL)-2, IL-4, IL-10, IL-13, eotaxin, and regulated upon activation normal T cell expressed and presumably secreted (RANTES) [32]. Here, IL10 is linked to atopic conjunctivitis.